TL;DR
The Pioneer: QLHC runs the I-SPY 2 TRIAL, the longest-running adaptive platform trial in history, designed to slash the time and cost of drug development.
The Friction: Their prior vendor was slow, costly, and engineering-heavy; setting up new research environments took days of manual configuration.
The Fix: QLHC launched OneSource AI (powered by LatchBio), a secure, white-labeled portal for instant data access and analysis.
The Impact: Project onboarding dropped from days to hours, platform costs were cut to ~1/3 of the prior solution, and adoption has surged across UCSF and partner sites.
Industry/Assays
Oncology clinical trials, biomarkers, medical imaging, high-dimensional genomics.
Based
San Francisco, CA
The Challenge
QLHC manages a massive, complex operation: a first-of-its-kind platform trial across 40 clinical sites with over 200 approved research studies. They needed to give hundreds of investigators secure access to sensitive biomarker, imaging, and genomic data without compromising privacy or speed.
Sensitive Data at Scale: Managing terabytes of patient data requires strict de-identification and privacy-preserving access controls.
Legacy Lag: The old platform relied on vendor engineers to manually copy and configure data. New projects took days to launch and incurred heavy support fees.
Cloud Conflict: Vendor lock-in with Azure clashed with QLHC's agile, AWS-first internal talent and tooling.
Usability Gap: Biologists needed a clean, intuitive UI to run analyses self-serve, without needing to learn command-line ops.
The Solution: OneSource AI on LatchBio
To unlock the full potential of their data, QLHC partnered with LatchBio to build OneSource AI, a custom-branded portal that matches QLHC's strict governance models while offering a modern user experience.
Scientific Autonomy: Scientists can now launch reproducible, containerized Nextflow pipelines with clear parameters and versioning. As Adam Asare puts it, the visibility is "very elegant and very cool."
Zero-Friction Access: Analysts can audit runs and biologists can self-serve data needs without waiting on DevOps tickets.
Privacy by Design: Controlled workspaces enable deep genomic analysis while minimizing re-identification risks.
True Partnership: A nimble collaboration with direct access to LatchBio's engineering team allowed for rapid iteration and white-glove support.
Real-World Impact
From Stalled to Accelerated: After a year of "no headway" onboarding researchers with the legacy tool, UCSF biologists now work completely within OneSource AI.
Instant Onboarding: "We can bring a project online within a few hours as opposed to days." — Adam Asare, CDO
Agile Support: The data team can now monitor runs in real-time, offering live assistance to investigators.
Financial Efficiency: Total platform costs were cut to roughly a third of the prior vendor's fees, freeing up resources for research.
Conclusion
By powering OneSource AI with LatchBio, Quantum Leap Healthcare replaced a slow, rigid legacy system with a nimble, scientist-centric platform. They now bring new projects online in hours, drastically reduce costs, and scale secure data access across 40 sites—empowering hundreds of researchers to work faster toward the next breakthrough in cancer care.